CME financial statements
The full income statement, balance sheet, and cash-flow statement for CME Group Inc. (CME), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 6.52B YoY+6.4% | 6.13B YoY+9.9% | 5.58B YoY+11.1% | 5.02B YoY+7.0% | 4.69B YoY-4.0% | |
| Amortization of intangibles | 223M YoY+0.8% | 222M YoY-2.2% | 227M YoY-0.5% | 228M YoY-4.2% | 238M YoY-23.7% | |
| Operating income | 4.23B YoY+7.6% | 3.93B YoY+14.4% | 3.44B YoY+13.9% | 3.02B YoY+14.0% | 2.65B YoY+0.3% | |
| Other non-operating income | -4.83B YoY-32.1% | -3.66B YoY+22.1% | -4.69B YoY-152.1% | -1.86B YoY-643.6% | 343M YoY+379.9% | |
| Equity-method income | 372M YoY+5.9% | 351M YoY+18.2% | 297M YoY-1.4% | 301M YoY+22.5% | 246M YoY+29.0% | |
| Pre-tax income | 5.33B YoY+17.4% | 4.54B YoY+9.3% | 4.15B YoY+19.0% | 3.49B YoY+3.5% | 3.37B YoY+23.9% | |
| Income tax | 1.26B YoY+23.9% | 1.02B YoY+9.5% | 927M YoY+16.0% | 799M YoY+8.5% | 737M YoY+19.7% | |
4.07B YoY+15.5% | 3.53B YoY+9.3% | 3.23B YoY+19.9% | 2.69B YoY+2.0% | 2.64B YoY+25.2% | ||
$11.16 YoY+15.4% | $9.67 YoY+9.1% | $8.86 YoY+19.7% | $7.40 YoY+1.5% | $7.29 YoY+24.2% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
165B YoY+60.5% | 103B YoY+8.6% | 94.9B YoY-31.8% | 139B YoY-14.0% | 162B YoY+81.2% | ||
198B YoY+44.4% | 137B YoY+6.0% | 130B YoY-25.5% | 174B YoY-11.5% | 197B YoY+57.9% | ||
160B YoY+56.7% | 102B YoY+9.5% | 93.4B YoY-32.2% | 138B YoY-14.2% | 160B YoY+81.9% | ||
170B YoY+52.9% | 111B YoY+7.8% | 103B YoY-30.1% | 147B YoY-13.0% | 169B YoY+72.3% | ||
28.7B YoY+8.5% | 26.5B YoY-0.9% | 26.7B YoY-0.5% | 26.9B YoY-1.9% | 27.4B YoY+4.0% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
4.28B YoY+15.9% | 3.69B YoY+6.9% | 3.45B YoY+13.0% | 3.06B YoY+27.2% | 2.40B YoY-11.5% | ||
1.50B YoY+1914.5% | -82.6M YoY-495.2% | 20.9M YoY+104.3% | -490M YoY-938.7% | 58.4M YoY+133.3% | ||
56.5B YoY+1013.2% | 5.08B YoY+110.5% | -48.3B YoY-90.4% | -25.4B YoY-136.3% | 69.9B YoY+48.0% | ||
| Net change in cash | 62.3B YoY+617.2% | 8.68B YoY+119.4% | -44.9B YoY-96.6% | -22.8B YoY-131.5% | 72.4B YoY+45.4% | |
| Interest paid | 136M YoY+4.4% | 130M YoY+0.0% | 130M YoY-2.5% | 133M YoY-0.1% | 133M YoY+0.0% | |
| Income taxes paid | 1.16B YoY-2.7% | 1.20B YoY+11.6% | 1.07B YoY+10.1% | 973M YoY+28.9% | 755M YoY+15.7% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 4.04B YoY+0.0% | 4.04B YoY+0.0% | 4.04B YoY+0.0% | 4.04B YoY+0.0% | 4.04B YoY+0.0% | |
| P/E | 4.2× YoY+0.0% | 4.2× YoY+0.0% | 4.2× YoY+0.0% | 4.2× YoY+0.0% | 4.2× YoY+0.0% | |
| P/S | 1.3× YoY+0.0% | 1.3× YoY+0.0% | 1.3× YoY+0.0% | 1.3× YoY+0.0% | 1.3× YoY+0.0% | |
| P/B | 0.2× YoY+0.0% | 0.2× YoY+0.0% | 0.2× YoY+0.0% | 0.2× YoY+0.0% | 0.2× YoY+0.0% | |
| P/FCF | 3.4× YoY+0.0% | 3.4× YoY+0.0% | 3.4× YoY+0.0% | 3.4× YoY+0.0% | 3.4× YoY+0.0% | |
| Earnings yield | 23.5% YoY+0.0% | 23.5% YoY+0.0% | 23.5% YoY+0.0% | 23.5% YoY+0.0% | 23.5% YoY+0.0% | |
| FCF yield | 29.7% YoY+0.0% | 29.7% YoY+0.0% | 29.7% YoY+0.0% | 29.7% YoY+0.0% | 29.7% YoY+0.0% | |
| Dividend yield | 8.2% YoY-51.9% | 17.1% YoY+7.8% | 15.9% YoY+13.5% | 14.0% YoY+44.1% | 9.7% YoY+0.0% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: CME's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CME filings on SEC EDGAR → Not investment advice.
